Aclaris Therapeutics (ACRS) – Investment Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Aclaris Therapeutics (NASDAQ: ACRS) recently:

  • 7/8/2019 – Aclaris Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 6/28/2019 – Aclaris Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 6/27/2019 – Aclaris Therapeutics was downgraded by analysts at Svb Leerink Llc from an “outperform” rating to a “market perform” rating.
  • 6/27/2019 – Aclaris Therapeutics was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating.
  • 6/13/2019 – Aclaris Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 6/12/2019 – Aclaris Therapeutics had its price target lowered by analysts at Cantor Fitzgerald from $50.00 to $24.00. They now have an “overweight” rating on the stock.
  • 6/7/2019 – Aclaris Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
  • 5/21/2019 – Aclaris Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

ACRS stock traded down $0.02 during midday trading on Friday, reaching $2.18. The company’s stock had a trading volume of 315,008 shares, compared to its average volume of 615,380. Aclaris Therapeutics Inc has a 52 week low of $1.93 and a 52 week high of $20.80. The stock has a market capitalization of $96.16 million, a PE ratio of -0.54 and a beta of 0.77. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.30 and a current ratio of 4.33. The stock’s 50-day moving average price is $4.03.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.05). Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%. The business had revenue of $5.04 million during the quarter, compared to the consensus estimate of $5.13 million. Analysts predict that Aclaris Therapeutics Inc will post -2.87 earnings per share for the current year.

In other news, major shareholder James E. Flynn sold 699,475 shares of Aclaris Therapeutics stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $2.69, for a total transaction of $1,881,587.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder James E. Flynn sold 454,261 shares of Aclaris Therapeutics stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $4.59, for a total transaction of $2,085,057.99. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,107,983 shares of company stock worth $9,303,479. Insiders own 14.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citigroup Inc. lifted its holdings in shares of Aclaris Therapeutics by 3,200.0% during the 4th quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 3,872 shares during the period. Great West Life Assurance Co. Can acquired a new position in Aclaris Therapeutics during the 4th quarter worth approximately $43,000. BNP Paribas Arbitrage SA increased its position in Aclaris Therapeutics by 82,200.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 7,398 shares in the last quarter. Legal & General Group Plc increased its position in Aclaris Therapeutics by 64.1% during the 4th quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,536 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Aclaris Therapeutics in the 1st quarter valued at approximately $70,000. 91.79% of the stock is currently owned by institutional investors.

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Read More: What is the return on assets (ROA) ratio?

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.